Randomized Controlled Trial of Olanzapine for the Control of Chemotherapy-inducedVomiting in Children Receiving Highly Emetogenic Chemotherapy
Study of Olanzapine in Children Receiving Chemotherapy for Hematopoietic Stem Cell Transplant (HSCT)
Sponsor: The Hospital for Sick Children Research Institute
Enrolling: Male and Female Patients
IRB Number: AAAS8602
U.S. Govt. ID: NCT03118986
Contact: Diane George, MD: 212-305-2466 / dg2039@cumc.columbia.edu
Additional Study Information: This research study is to find out whether adding olanzapine to standard antiemetics will be helpful in controlling chemotherapy-induced vomiting (CINV) in children receiving high-dose cyclophosphamide for Blood/Bone Marrow Transplant (BMT) conditioning.
This study is closed
Investigator
Diane George, MD
Do You Qualify?
Are you or your child between the ages of 2.5-18? Yes No
Do you or your child have a planned Allogeneic Hematopoietic stem cell transplant? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Diane George, MD
dg2039@cumc.columbia.edu
212-305-2466